Trial Profile

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Cisplatin
Indications Bladder cancer; Carcinoma; Urogenital cancer
Focus Adverse reactions
Acronyms PCR-MIB

Most Recent Events

27 Jan 2025 Status changed from active, no longer recruiting to completed.
13 Sep 2022 Results of safety and efficacy , presented at the 47th European Society for Medical Oncology Congress
14 Feb 2022 Planned primary completion date changed from 1 Sep 2023 to 31 Mar 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com